Search results for "DIABETES MELLITUS"

showing 10 items of 2077 documents

Should kidney allografts from old donors be allocated only to old recipients?

2020

Contains fulltext : 226016.pdf (Publisher’s version ) (Closed access) In several deceased donor kidney allocation systems, organs from elderly donors are allocated primarily to elderly recipients. The Eurotransplant Senior Program (ESP) was implemented in 1999, and since then, especially in Europe, the use of organs from elderly donors has steadily increased. The proportion of ≥60-year-old donors reported to the Collaborative Transplant Study (CTS) by European centers has doubled, from 21% in 2000-2001 to 42% in 2016-2017. Therefore, in the era of organ shortage it is a matter of debate whether kidney organs from elderly donors should only be allocated to elderly recipients or whether <65-y…

medicine.medical_specialtyTissue and Organ ProcurementMedizinEconomic shortage030230 surgeryKidneyold donors03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIncreased creatininemedicineHumanskidney allograftsAgedDeceased donor kidneyKidneyTransplantationbusiness.industryGraft SurvivalAge FactorsCancerMiddle Agedmedicine.diseaseAllograftsKidney TransplantationTissue DonorsEuropekidney allografts ; old donors ;Marginal donormedicine.anatomical_structureDonation030211 gastroenterology & hepatologyRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]business
researchProduct

Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

2021

Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients …

medicine.medical_specialtyTranscatheter aorticVentricular Function Leftlaw.inventionTranscatheter Aortic Valve Replacementchemistry.chemical_compoundRandomized controlled trialGlucosideslawInternal medicineDiabetes mellitusmedicineHumansProspective StudiesDapagliflozinBenzhydryl CompoundsHeart FailureEjection fractionbusiness.industryStroke VolumeAortic Valve Stenosismedicine.diseaseStenosisTreatment OutcomechemistryHeart failureAortic ValveCardiologyCardiology and Cardiovascular MedicinebusinessKidney diseaseEuropean journal of heart failureReferences
researchProduct

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis

2018

Abstract Background Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset. Methods Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed. BMI, waist circumference, lipids, glycemia, HbA1c, insulin requirement, glutamic oxaloacetic and glutam…

medicine.medical_specialtyType 1 diabetemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissue030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologyCardiovascular risk factorSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusmedicineInternal Medicinec-Peptideslcsh:RC620-627Cardiovascular risk factorsType 1 diabetesC-Peptidebusiness.industryInsulinResearchInsulin secretionInsulin resistancemedicine.diseaseKetoacidosislcsh:Nutritional diseases. Deficiency diseasesType 1 diabetesSteatosisC-Peptides; Cardiovascular risk factors; Insulin resistance; Insulin secretion; Type 1 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolismbusiness
researchProduct

Diabetic Retinopathy. Association with Metabolic Compensation, Duration of Diabetes and Other Micro and Macrovascular Complications in Patients with …

2020

Summary Introduction Diabetic retinopathy (DR) is a severe complication that can lead to complete vision loss and still is one of the main blindness-causing reasons among patients with type 1 diabetes mellitus (T1DM). DR as a complication can cause vision loss to people at their working age. More than 90% of patients with type 1 diabetes will develop DR by 20 years post diagnosis (Leslie R. Dye, 2018). DR is more likely to develop in patients with T1DM (Kanski's Clinical Ophthalmology, 2016). This complication can be very serious speaking of the ability to see. Sometimes vitrectomy plays a vital role in the management of severe complications of DR at its end-stage (Myron Yanoff et al., 2020…

medicine.medical_specialtyType 1 diabetesbusiness.industry030209 endocrinology & metabolismDiabetic retinopathymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineGeneral Materials ScienceIn patient030212 general & internal medicineDuration (project management)businessActa Chirurgica Latviensis
researchProduct

Abstract 412: The Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Improves Diabetic Complications in the Streptozotocin Type 1 Diabetes Mellit…

2014

Objectives: In diabetes, cardiovascular complications are associated with endothelial dysfunction and oxidative stress. Empagliflozin (Empa), as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i) in clinical development, offers a promising novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with Empa could improve endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated oxidative stress. Research Design and Methods: Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection Empa…

medicine.medical_specialtyType 1 diabetesbusiness.industryType 2 diabetesmedicine.diseasemedicine.disease_causeStreptozotocinEndocrinologyInternal medicineDiabetes mellitusmedicineEmpagliflozinEndothelial dysfunctionSGLT2 InhibitorCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Gender differences related to the presence of atrial fibrillation in older hypertensive patients

2013

AIM: To determine whether there are gender differences in the epidemiological profile of atrial fibrillation (AF) and to characterise the clinical, biochemical, and therapeutic factors associated with AF. METHODS: Each investigator (primary care physicians or physicians based in hospital units for hypertension treatment) recruited the first 3 patients with an age of ≥ 65 years and a clinical diagnosis of hypertension (ambulatory blood pressure monitoring and an electrocardiogram, were performed) on the first working day of the week for 5 wk and identified those individuals with atrial fibrillation. A binary logistic regression was performed, including all of the variables that were signific…

medicine.medical_specialtyUnivariate analysisPediatricsAmbulatory blood pressureBrief ArticleHeart diseaseMedicinabusiness.industryAtrial fibrillationmacromolecular substancesmedicine.diseaseAnginaInternal medicineDiabetes mellitusEpidemiologymedicineCorMyocardial infarctionCardiology and Cardiovascular MedicinebusinessWorld Journal of Cardiology
researchProduct

Colorectal Cancer in Patients with Type 2 Diebetes Mellitus: Retrospective Analysis of 741 Cases

2012

ABSTRACT Background Understanding the risk factors of colorectal cancer (CRC) is crucial to the development of effective strategies for its prevention. Type 2 diabetes mellitus (DM) is associated with increased CRC risk and epidemiological studies identified a correlation between these diseases. Aim: To evaluate prevalence of CRC in a cohort of Caucasian patients with type 2 DM and the association with other variables previously known to be related with increased CRC. Methods We retrospectively evaluated 741 DM 2 patients followed in our institution of southern Italy between 2000-2008 for the incidence of CRC. Patients were stratified based on gender, age, body mass index (BMI), alcohol and…

medicine.medical_specialtyUnivariate analysisbusiness.industryIncidence (epidemiology)Type 2 Diabetes MellitusHematologymedicine.diseasechemistry.chemical_compoundOncologychemistryMedian follow-upInternal medicineDiabetes mellitusCohortMedicineGlycated hemoglobinbusinessBody mass indexAnnals of Oncology
researchProduct

249 Validation of assessment of circulate oxidative stress markers by the Free Oxygen Radicals Testing (FORT) assay among patients with an acute myoc…

2011

BackgroundFree oxygen radicals play an important role in the pathogenesis of many diseases including cardiovascular diseases, diabetes, cancer and aging. Several methods were developed for the direct or indirect measurement of oxygen free radical and its by-products. Using a new Free Oxygen Radicals Testing (FORT) the current study is designed first to validate the device and to investigate the potential relationships between the ROS and clinical or biological factors in human serum from a population of men with an acute myocardial infarction (AMI).MethodsWe first determined the effect of storage, variability and reproducibility of the FORT test in serum. Then we used the test in 66 patient…

medicine.medical_specialtyUnivariate analysiseducation.field_of_studyEjection fractionbusiness.industryPopulationCancermedicine.disease_causemedicine.diseaseSurgeryPathogenesisDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinesseducationOxidative stressArchives of Cardiovascular Diseases Supplements
researchProduct

CT imaging of acute and chronic pyelonephritis: a practical guide for emergency radiologists

2020

Contrast-enhanced CT is not routinely indicated in uncomplicated urinary infections, but it may be necessary in patients with specific risk factors (i.e., diabetes, immunocompromised patients, history of stones, or prior renal surgery) or in patients not responding to antibiotics and in detecting complications of pyelonephritis. CT is the gold standard for imaging assessment of pyelonephritis severity. Imaging appearance of acute pyelonephritis, including focal (i.e., wedge-shaped zones of decreased attenuation or hypodense mass) and diffuse (i.e., global enlargement, poor parenchymal enhancement, lack of excretion of contrast, fat stranding) forms, needs to be differentiated from renal inf…

medicine.medical_specialtyUrinary systemInterstitial nephritisContrast MediaMalignancy030218 nuclear medicine & medical imagingMuscle hypertrophyDiagnosis DifferentialComputed tomography Pyelonephritis Emergency Kidney03 medical and health sciences0302 clinical medicineAtrophyDiabetes mellitusmedicineHumansRadiology Nuclear Medicine and imagingKidneyPyelonephritisbusiness.industry030208 emergency & critical care medicineGold standard (test)medicine.diseasemedicine.anatomical_structureAcute DiseaseChronic DiseaseEmergency MedicineRadiologybusinessTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct